期刊
ONCOGENE
卷 26, 期 50, 页码 7163-7169出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.onc.1210528
关键词
herceptin; trastuzumab; ERBB2; breast cancer; phosphorylation; tyrosine kinase
Breast cancers that overexpress the ERBB2 tyrosine kinase receptor may be treated with the recombinant humanized monoclonal anti-ERBB2 antibody trastuzumab (herceptin). However, resistance to this targeted therapy is frequent. We have determined the response of 18 breast tumor cell lines to trastuzumab and compared it with the ERBB2 phosphorylation status using antibodies directed against tyrosine residue 1248. We show that sensitivity to trastuzumab is frequently associated with the expression of a phosphorylated ERBB2 protein.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据